Artemis Resources Limited (“Artemis” or “the Company”) (ASX: ARV) advises that it
has signed a Sale and Purchase Agreement (“SPA”) by which Artemis will sell its 4
million Novo Resources Corp. (“Novo”) shares to Canadian mining company, Kirkland
Lake Gold Ltd (ASX:KLA, TSE:KL) (“Kirkland Lake Gold”), for total gross proceeds of
A$20.7 million, being the Australian dollar (AUD) equivalent of Canadian dollars (CAD)
$5.00 per Novo share (using an exchange rate of 1 CAD = 1.04 AUD).
The share sale transaction was arranged on an unsolicited basis. Completion of the
share sale transaction will significantly strengthen the Company’s balance sheet and
provide significant funds to explore and develop its own conglomerate gold
assessmentstrategy and to continue Artemis’sfocus on bringing its broad base metals,
cobalt and gold asset base in to production, with no dilution to shareholders.
As a condition to completion, Novo shall release Artemis from the contractual 12
month hold period for these shares, which was originally due to expire in August this
year. Deal closing is expected by the end of May.
David Lenigas, Artemis’s Executive Chairman, commented;
“This $20 million deal willsignificantly boost Artemis’s cash reserves without diluting
shareholders. Our 50% interest in the exciting Novo/Artemis joint venture in the
Karratha area remains unchanged and we are well funded to continue paying our
share of JV expenses. Artemis believes that the decision by Kirkland Lake Gold to
increase its position in Novo is further evidence of the strength in the conglomerate
and paleo placer gold story.”
- Forums
- ASX - By Stock
- ARV
- Ann: Artemis Signs Novo Share Sale Deal to Bank $20 million
Ann: Artemis Signs Novo Share Sale Deal to Bank $20 million, page-6
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ARV (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
-0.001(9.09%) |
Mkt cap ! $19.16M |
Open | High | Low | Value | Volume |
1.1¢ | 1.1¢ | 1.0¢ | $36.62K | 3.486M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 6127936 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 2451489 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 6127936 | 0.010 |
7 | 1663440 | 0.009 |
4 | 2020000 | 0.008 |
5 | 4137142 | 0.007 |
3 | 4583333 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 2451489 | 1 |
0.012 | 962596 | 5 |
0.013 | 1592062 | 6 |
0.014 | 1326916 | 2 |
0.015 | 666278 | 6 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
ARV (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online